Company Profile
Adhering to the vision of "innovation for the great majority", Qyuns Therapeutics (2509.HK),as a high-tech enterprise focuses on R&D, industrialization and commercialization of antibody drugs for autoimmune and allergic diseases, and strives to improve drug accessibility and affordability.
Based on our independent innovation capabilities, the company has built a comprehensive pipeline, including 1 product approved by NMPA, 2 products at phase III clinical stage, 4 products at phase II or phase I, with indications covering the four major disease areas of skin, respiratory, digestive, and rheumatism. We are one of the leading companies in China in the field of autoimmune and allergic diseases. We are one of those who received the most IND approvals regarding autoimmune and allergic diseases in China. Meanwhile, through the commercialization cooperation with Huadong Medicine and other strategic partners, Qyuns is able to build an integrated layout of the whole industrial chain of R&D, production and sales, and the development certainty is further enhanced.
Qyuns Therapeutics, as a national high-tech enterprise, has applied for more than 100 invention patents domestically and overseasglobally. It has also been recognized as a potential unicorn enterprise by Productivity Centre of Jiangsu Province.